PARP1 and neoplasm: In Phase III trials, olaparib, a PARP inhibitor, demonstrated significantly prolonged radiographic PFS in patients with mCRPC compared to enzalutamide or abiraterone.390 Tumor vascular receptors represent attractive targets for ligand-directed drug discovery and development.